Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2019

Cash equivalents and available-for-sale securities consisted of the following (in thousands):


	September 30, 2019
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Money market funds	$	16,381	$	—	$	—	$	16,381
Corporate bonds		28,083		23		(1)		28,105
Commercial paper		40,868		—		(3)		40,865
Government bonds		46,579		17		—		46,596
Total cash equivalents and available-for-sale securities	$	131,911	$	40	$	(4)	$	131,947
Classified as:
Cash equivalents							$	44,450
Available-for-sale securities								87,497
Total cash equivalents and available-for-sale securities							$	131,947


	December 31, 2018
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Money market funds	$	25,390	$	—	$	—	$	25,390
Corporate bonds		8,997		—		(8)		8,989
Commercial paper		59,730		—		—		59,730
Government bonds		33,423		—		(29)		33,394
Total cash equivalents and available-for-sale securities	$	127,540	$	—	$	(37)	$	127,503
Classified as:
Cash equivalents							$	80,883
Available-for-sale securities								46,620
Total cash equivalents and available-for-sale securities							$	127,503

Property and equipment, net consisted of the following (in thousands):


	September 30,		December 31,
	2019		2018
Laboratory equipment	$	3,006	$	2,533
Furniture and computer equipment		487		338
Leasehold improvements		800		67
Total property and equipment		4,293		2,938
Less: accumulated depreciation and amortization		(2,559)		(2,077)
Property and equipment, net	$	1,734	$	861

Accrued expenses and other payables consisted of the following (in thousands):


	September 30,		December 31,
	2019		2018
Accrued clinical and research related expenses	$	6,420	$	7,781
Accrued employee related expenses		3,480		2,726
Accrued professional service fees		376		61
Other		210		595
Total accrued expenses and other payables	$	10,486	$	11,163